Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2B | P67870 | 2/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.36 |
| ▸ | TTK | P33981 | 9/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CDK7 | P50613 | 1/20 | 0.33 |
| ▸ | CCNH | P51946 | 1/20 | 0.33 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1528130 | 1.00 | CSNK2B (0.60) | CSNK2BCSNK2A2TTKKCNH2CYP3A4 | |
| SCHEMBL12768843 | 0.92 | CSNK2B (0.72) | CSNK2BCSNK2A2TTKKCNH2CYP3A4 | |
| SCHEMBL1487854 | 0.92 | CSNK2B (0.72) | CSNK2BCSNK2A2TTKKCNH2CYP3A4 | |
| SCHEMBL12841222 | 0.91 | CSNK2B (0.60) | CSNK2BCSNK2A2TTKKCNH2CYP3A4 | |
| SCHEMBL1487850 | 0.89 | CSNK2B (0.63) | CSNK2BCSNK2A2KCNH2CDK2TYK2 | |
| SCHEMBL1487851 | 0.89 | CSNK2B (0.63) | CSNK2BCSNK2A2KCNH2CDK2TYK2 | |
| SCHEMBL12841020 | 0.89 | CSNK2B (0.53) | CSNK2BCSNK2A2TTKKCNH2CYP3A4 | |
| SCHEMBL1527866 | 0.88 | CSNK2B (0.55) | CSNK2BCSNK2A2CDK1CCNE1CDK2 | |
| SCHEMBL1527867 | 0.88 | CSNK2B (0.55) | CSNK2BCSNK2A2CDK1CCNE1CDK2 | |
| SCHEMBL1527856 | 0.87 | CSNK2B (0.54) | CSNK2BTTKKCNH2CYP3A4CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | CYLENE PHARMACEUTICALS, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110071115-A1 | PHARMACEUTICALLY USEFUL HETEROCYCLE-SUBSTITUTED LACTAMS | PIM2, PIM1, PIM3 | CSNK2B 17/4885CSNK2A2 9/4885TTK 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.